THE APPLICATION OF COMBINED PREPARATIONS WITH CONSTANT DOSES OF ANTIHYPERTENSIVE DRUGS AS THE INITIAL TACTICS OF TREATMENT AT HIGH BLOOD PRESSURE LEVEL: PROVEN FACTS AND EXPERT’S OPINION-Reference-Cited by-同舟云学术

THE APPLICATION OF COMBINED PREPARATIONS WITH CONSTANT DOSES OF ANTIHYPERTENSIVE DRUGS AS THE INITIAL TACTICS OF TREATMENT AT HIGH BLOOD PRESSURE LEVEL: PROVEN FACTS AND EXPERT’S OPINION

Published:2021-05-29 Issue:2 Volume: Page:92-102
ISSN:2305-0748
Container-title:Eurasian heart journal
language:
Short-container-title:Evrazijskij kardiologičeskij žurnal

Author:

Gilyarevskij S. R.¹^ORCID,Bendeliani N. G.²^ORCID,Golshmid M. V.³^ORCID,Kuz’mina I. M.⁴^ORCID,Andreeva I. G.⁵

Affiliation:

1. National Medical Research Center For Therapy And Preventive Medicine Of The Ministry Of Health Of Russia; Russian Medical Academy Of Continuing Professional Education Of The Ministry Of Health Of Russia

2. Institute Of Coronary And Vascular Surgery, Consultative And Diagnostic Center, A.N. Bakulev NMRCCVS Of The Ministry Of Health Of Russian Federation

3. Russian Medical Academy Of Continuing Professional Education Of The Ministry Of Health Of Russia

4. N.V. Sklifosovsky Research Institute For Emergency Medicine

5. Moscow Social Pedagogical Institute,

Publisher

Intermedservice Ltd

Reference86 articles.

1. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environ- mental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1923—1994. doi: 10.1016/S0140-6736(18)32225-6.

2. Mills K.T., Bundy J.D., Kelly T.N., Reed J.E., Kearney P.M., Reynolds K., Chen J., He J. Global disparities of hypertension prevalence and con- trol: a systematic analysis of population-based studies from 90 countries. Circulation 2016;134:441—450.

3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 populationbased measurement studies with 19•1 million participants. Lancet 2017;389(10064):37—55. doi: 10.1016/S0140-6736(16)31919-5. Erratum in: Lancet 2020;396(10255):886.

4. SPRINT Research Group, Wright J.T. Jr, Williamson J.D., Whelton P.K., Snyder J.K., Sink K.M., Rocco M.V., Reboussin D.M., Rahman M., Oparil S., Lewis C.E., Kimmel P.L., Johnson K.C., Goff D.C. Jr, Fine L.J., Cutler J.A., Cushman W.C., Cheung A.K., Ambrosius W.T. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015;373:2103—2116. doi: 10.1056/NEJMoa1511939.

5. Vaduganathan M., Claggett B.L., Juraschek S.P., Solomon S.D. Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Cardiol 2020;5:576—581. doi: 10.1001/jamacardio.2019.6192.